<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030912</url>
  </required_header>
  <id_info>
    <org_study_id>C09040</org_study_id>
    <nct_id>NCT02030912</nct_id>
  </id_info>
  <brief_title>Effect of Minocycline &amp; Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas</brief_title>
  <acronym>ANTIRESDEV</acronym>
  <official_title>Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helperby Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helperby Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, open labelled study design is selected in order to determine the emergence and&#xD;
      persistence of antibiotic resistant bacteria in humans and on the composition of the&#xD;
      indigenous microbiotas at various body sites. These will involve the administration to&#xD;
      volunteers of minocycline and amoxicillin- a control group will receive a placebo.&#xD;
      Microbiology of the skin, saliva, faecal, skin and nasal micro flora, safety and adverse&#xD;
      events, vital signs, will be evaluated. The objectives of metagenomic analysis are:&#xD;
&#xD;
        -  To identify the in vivo molecular mechanisms responsible for antibiotic resistance and&#xD;
           its transfer in the indigenous oral and faecal microbiotas using metagenomics resistome&#xD;
           analysis.&#xD;
&#xD;
        -  To determine the impact of the use of antimicrobial agents on the oral resistome&#xD;
&#xD;
        -  To determine the impact of the use of antimicrobial agents on the faecal resistome&#xD;
&#xD;
        -  To determine the ecological impact of the use of antimicrobial agents on the relative&#xD;
           abundance of phylotypes of the indigenous oral microbiota&#xD;
&#xD;
        -  To determine the ecological impact of the use of antimicrobial agents on the relative&#xD;
           abundance of phylotypes of the indigenous faecal microbiotas&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of resistant bacteria collected from body sites in subjects receiving minocycline/ amoxicillin compared to the baseline.</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) will be monitored throughout the study</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Antibiotic Resistant Bacteria</condition>
  <arm_group>
    <arm_group_label>3 doses of amoxicillin daily for 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of minocycline daily for 5 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of placebo daily for 5 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 doses of amoxicillin daily for 7 days</intervention_name>
    <arm_group_label>3 doses of amoxicillin daily for 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 doses of minocycline daily for five days</intervention_name>
    <arm_group_label>2 doses of minocycline daily for 5 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 doses of placebo daily for five days</intervention_name>
    <arm_group_label>2 doses of placebo daily for 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged between 18 and 40 years.&#xD;
&#xD;
          2. Following verbal &amp; written information about the trial, the subject has signed &amp; dated&#xD;
             informed consent before any study related activity was carried out.&#xD;
&#xD;
          3. Subject legally competent and able to communicate effectively with the study personnel&#xD;
&#xD;
          4. Normal finding in the medical history and physical examination, unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant.&#xD;
&#xD;
          5. Male or female subjects who are using a medically acceptable method of contraception&#xD;
             or of non-childbearing potential (i.e., surgically sterile-bilateral tubal ligation or&#xD;
             removal of both ovaries and/or uterus at least 6 months prior to dosing or naturally&#xD;
             postmenopausal for at least one year with a Screening FSH leveâ‰¥l 40 mIU/L). - - A&#xD;
             negative serum pregnancy test is required at Screening for females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Regular use of medication, except contraceptive, vitamin tablets, treatment with&#xD;
             antimicrobial agents within the 3 months preceding the study, Use of antibiotics for 4&#xD;
             weeks prior to the study drug application or use of concomitant systemic or topical&#xD;
             antibiotics, Systemic treatment with immunosuppressive drugs e.g. cyclosporine,&#xD;
             azathioprine or oral corticosteroids within 4 weeks prior to baseline visit (Visit 2)&#xD;
             .&#xD;
&#xD;
          2. Participation in a trial with another investigational drug within the 3 months&#xD;
             preceding the study&#xD;
&#xD;
          3. Present or residual gastrointestinal, renal insufficiency or hepatic disorder&#xD;
&#xD;
          4. Abnormal pathology of nasal passages&#xD;
&#xD;
          5. Any clinically significant allergy or drug intolerance&#xD;
&#xD;
          6. Active hay fever, on-going cold/flu symptoms, including rhinitis at baseline (visit 2)&#xD;
&#xD;
          7. Any medical history of renal insufficiency or hepatic disorder or other conditions&#xD;
             known to interfere with the absorption, distribution, metabolism or excretion of drugs&#xD;
&#xD;
          8. history of hypersensitivity to beta-lactams or tetracycline&#xD;
&#xD;
          9. pregnant or breast-feeding women&#xD;
&#xD;
         10. Subjects known or suspected of not being able to comply with trial protocol (e.g.&#xD;
             alcoholism, drug dependency, or psychological state). History of regular alcohol&#xD;
             consumption exceeding an average weekly intake of alcohol greater than 21 units for&#xD;
             female and 28 units for male.&#xD;
&#xD;
             One unit is equivalent to a half-pint of beer or one measure of spirits or one glass&#xD;
             of wine.&#xD;
&#xD;
         11. Subjects with known or suspected immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorg Taubel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE,</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>The impact of a number of different types of antibiotics</keyword>
  <keyword>The emergence and persistence of antibiotic resistance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

